++

Lung transplantation is a therapeutic consideration for many patients with nonmalignant end-stage lung disease, and it prolongs survival and improves quality of life in appropriately selected recipients. Since 1985 more than 25,000 procedures have been recorded worldwide, and ~2200 transplants have been reported annually in recent years.

++

Indications

++

The indications span the gamut of lung diseases. The most common indications in the last few years have been chronic obstructive pulmonary disease (COPD), ~30%; idiopathic pulmonary fibrosis (IPF), ~30%; cystic fibrosis (CF), ~15%; α1-antitrypsin deficiency emphysema, ~3%; and idiopathic pulmonary arterial hypertension (IPAH), ~2%. Other diseases have accounted for the balance of primary indications, and retransplantation has accounted for ~4% of procedures.

++

Recipient Selection

++

Transplantation should be considered when other therapeutic options have been exhausted and when the patient's prognosis is expected to improve as a result of the procedure. Survival rates after transplantation can be compared with predictive indices for the patient's disease, but each patient's clinical course must be integrated into the assessment, too. Moreover, quality of life is a primary motive for transplantation for many patients, and the prospect of improved quality-adjusted survival is often attractive even if the survival advantage itself may be marginal.

++

Disease-specific consensus guidelines for referring patients for evaluation and for proceeding with transplantation are summarized in Table 266-1 and are linked to clinical, physiologic, radiographic, and pathologic features that influence the prognosis of the respective diseases. Candidates for lung transplantation are also thoroughly screened for comorbidities that might affect the outcome adversely. Conditions such as systemic hypertension, diabetes mellitus, gastroesophageal reflux, and osteoporosis are not unusual, but if uncomplicated and adequately managed, they do not disqualify patients from transplantation. The upper age limit is ~65–70 years at most centers.

++
Table Graphic Jump Location
Table 266-1 Disease-Specific Guidelines for Referral and Transplantation 

Want access to your institution's subscription?

Sign in to your MyAccess Account while you are actively authenticated on this website via your institution (you will be able to tell by looking in the top right corner of any page – if you see your institution’s name, you are authenticated). You will then be able to access your institute’s content/subscription for 90 days from any location, after which you must repeat this process for continued access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess account, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessMedicine Full Site: One-Year Subscription

Connect to the full suite of AccessMedicine content and resources including more than 250 examination and procedural videos, patient safety modules, an extensive drug database, Q&A, Case Files, and more.

$995 USD
Buy Now

Pay Per View: Timed Access to all of AccessMedicine

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.